Business Wire

Oral-B ® Announces Launch of THE BIG RETHINK, an Initiative to Make Oral Care More Inclusive, Accessible, and Positive for People With Disabilities, Their Caregivers, and Dental Professionals.

Share

Oral-B, a leading innovator in oral health is on a mission to change this with the launch of THE BIG RETHINK, its social ambition to ensure that everybody has an equitable oral care experience - whether that’s at home or in the dentist’s chair. The brand, who is at the beginning of this journey recognizes the need to continue learning from both dental professionals and consumers who frequently experience oral health struggles to be able to make a real impact and offer an equitable oral care experience for everyone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006117/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Oral-B launches The Big Rethink initiative at exclusive launch event in Frankfurt with panel of experts on how to make oral care more inclusive and accessible. Pictured (left to right): British broadcaster, Nikki Fox, Executive Board Member of the iADH, Alison Dougall, British influencer James Hunt from Stories About Autism, iADH spokesperson, Johanna Norderyd, popular German actor, Andre Dietz, Chief Executive Officer for Healthcare, Jennifer Davis and P&G Europe Oral Care Senior Vice President, Benjamin Binot. (Photo: Business Wire)

To launch THE BIG RETHINK campaign, the brand is working together with the International Association for Disability and Oral Health (iADH) to help inform the approach. The first step of this partnership is the launch of the ‘Positive Practices’ programme, designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients. The programme will not only enable Oral-B to become more educated on the physical and mental needs of those with different types of disabilities, but it will also help them to learn how to adapt their product offering and improve the oral health outcomes of those with disabilities. THE BIG RETHINK Content Hub will also offer relevant and helpful content for people with disabilities, their caregivers and families, as well as the professional dental health community. Visit: https://www.oralb.co.uk/en-gb/big-rethink.

As Oral-B celebrates 60 years since the launch of the first electric toothbrush in 1963, the brand continues to put consumer understanding and leading-edge technology at the heart of its product development by designing inclusive products that help to bring about positive change in oral care for everyone. The brand is also developing a series of tools to support dentists within their practices, such as student training and accreditation programmes.

To celebrate the launch of THE BIG RETHINK, a brand film was unveiled last night at an exclusive launch event in Frankfurt, Germany. The event was an opportunity for Oral-B to set out its ambitions of THE BIG RETHINK and discuss the findings of The Oral Health & Disability European Study with an influential panel of speakers. Including P&G’s Chief Executive Officer for Healthcare, Jennifer Davis, iADH spokesperson, Johanna Norderyd, British broadcaster, Nikki Fox, British influencer James Hunt from Stories About Autism and popular German actor, Andre Dietz.

Jennifer Davis, P&G Chief Executive Officer, Healthcare says: “As a leading innovator in oral health for over 70 years and the world’s #1 dentist recommended toothbrush brand, we recognise the importance of making oral care accessible to all. We are indeed at the beginning of a very exciting journey, and we will continue to learn from both dental professionals and consumers to ensure we are creating positive oral care solutions for everyone – I really believe that this is the beginning of an initiative that has a global footprint.”

Benjamin Binot, P&G Europe Oral Care Senior Vice President comments: “Addressing the significant oral health inequalities experienced by people with disabilities in Europe is a huge priority for Oral-B. Our research shows that today, there are many oral health struggles amongst this audience – 1 in 5 (20%) of those with severe disabilities find brushing all their teeth physically challenging* and over a third of people with disabilities feel anxious or frustrated when it comes to visiting the dentist*. We want to help change this and believe that everyone should have an equitable oral health experience. Through our work with the iADH and the creation of the Positive Practices programme, we want to not only provide dental practices with educational materials to make their practices more inclusive, but also give the disabled community the tools they need to have more autonomy over their own oral health.

Alison Dougall, Professor in Special Care Dentistry, and an Executive Board member of iADH says; “We are delighted to have partnered with Oral-B to address the oral health struggles that are experienced by people with disabilities in Europe. Our shared values will enable us to make a huge difference to the oral care experience for people living with visible and nonvisible disabilities. We recognise that many healthcare professionals have not received education in special care dentistry during their training, and so by raising awareness around the issue and supporting those with disabilities, we can help to make small but significant adjustments to their oral health routines.”

-ENDS-

About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About the research
– The Oral Health & Disability European Study – UK, France, Germany and Italy, was conducted by Reputation Leaders.

– The studies were conducted between 2021 – 2022 in Germany (n=1034), France (n=1009), UK (n=2029) and Italy (n=1002). In each country the online survey sample was recruited and reported to be representative of the total adult population by age, gender and region.

– The margin of error of a sample of 5000 adults is +/- 1.4% at a 95% confidence level for the 4 leading economies.

– At a country level, the margin of error of the sample relative to the total adult population was UK n=2000 (+/- 2.2%), Germany, France and Italy, n=1000 (+/- 3.1%)

+ Assumes total EU and UK population, 2022

About The iADH (International Association for Disability and Oral Health)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.

For more information, please visit: https://www.oralb.co.uk

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR contact:
melany.whitworth@pgone.co.uk

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 13:57:00 CEST | Press release

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

HiddenA line styled icon from Orion Icon Library.Eye